All In Biotech

Drug Trial Radar · NCT07455006

Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of QL0911 in Pediatric Patients With Primary Immune Thrombocytopenia.

Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Apr 20, 2026

Primary completion

Dec 10, 2027

Study completion Mar 10, 2028

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate efficacy and of safety QL0911 in the treatment of thrombocytopenia in pediatric patients with previously treated chronic ITP.

Conditions

  • Thrombocytopenia, Immune

Interventions

  • QL0911Drug

    The starting dose of QL0911 is 1 µg/kg administered weekly by subcutaneous injection. Participants will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10\^9/L and ≤ 200 x 10\^9/L.

  • PlaceboDrug

    Matching placebo administered by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Durable Platelet ResponseTime frame: Week 18 to week 25

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.